drugset / Trial / NCT00576173
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the analgesic effectiveness and safety of 37.5mg Tramadol hydrochloride/325mg Acetaminophen in the treatment of breakthrough pain in cancer patients.
Timeline
- Start
- 2005-12
- Primary completion
- —
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetaminophen | Small molecule | 325 mg | Oral |
| Subject | Acetaminophen | Small molecule | 650 mg | Oral |
| Subject | Tramadol | Other / unclassified | 37.5 mg | Oral |
| Subject | Tramadol | Other / unclassified | 75 mg | Oral |
Indications
No indication recorded.